The rise in SRPT's share price can be attributed to the encouraging sales performance of its recently approved one-shot gene therapy for DMD.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards ...

On Wednesday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $137.94 which represents a slight increase of $7.44 or 5.70% from the prior close of $130.5. The stock opened ...

A Relative Strength Rating upgrade for Sarepta Therapeutics shows improving technical performance. Will it continue?

Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an ...

Amgen will present at the 7th Annual Evercore HealthCONx Conference at 10:00 a.m. ET on Wednesday, Dec. 4, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, Jay ...

PTC Therapeutics faces significant risks with its key revenue sources, Translarna and Emflaza. Find out why I am sticking ...

Bernstein lowered the firm’s price target on Arrowhead (ARWR) to $24 from $27 and keeps a Market Perform rating on the shares. The company’s ...

In recent weeks, global markets have experienced a broad-based rally with smaller-cap indexes outperforming large-caps, driven by strong labor market data and positive sentiment from economic ...

The head of MI6 says British security will be "jeopardised" if Putin is allowed to succeed in Ukraine, as he warned the spy agency has already uncovered a Russian sabotage campaign in Europe.